Aprea Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APRE research report →
Price Chart
About the company
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways.
- CEO
- Oren Gilad
- IPO
- 2019
- Employees
- 8
- HQ
- Boston, PA, US
Get TickerSpark's AI analysis on APRE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.87M
- P/E
- -0.59
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 0.88
- EV/EBITDA
- 2.72
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -46.72%
- ROIC
- -33.73%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-13,233,836
- Net Income
- $-12,599,569+2.8%
- EPS
- $-1.93+17.9%
- OCF Growth
- +4.9%
- FCF Growth
- +5.0%
- 52W High
- $1.69
- 52W Low
- $0.55
- 50D MA
- $0.73
- 200D MA
- $0.79
- Beta
- 1.63
- RSI (14)
- 33
- Avg Volume
- 274.92K
No earnings-call transcripts are available for APRE yet.
- Free Float
- 86.4%
- Shares Outstanding
- 12.38M
- Float Shares
- 10.70M
of shares held by institutions
22 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Aigh Capital Management LLC | 1.02M | 0 |
| Vestal Point Capital, LP | 350.00K | 0 |
| Sphera Funds Management Ltd. | 270.00K | 0 |
| Nantahala Capital Management, LLC | 205.76K | 0 |
| Renaissance Technologies LLC | 105.80K | ▲ 80.70K |
| Geode Capital Management, LLC | 74.87K | ▼ 44.26K |
| Citadel Advisors LLC | 58.60K | ▲ 58.60K |
| Vanguard Group Inc | 58.09K | ▼ 100.15K |
| Bnp Paribas Arbitrage, Snc | 45.21K | ▲ 5.39K |
| Diadema Partners LP | 44.91K | ▲ 44.91K |
| Vanguard Fiduciary Trust Co | 38.46K | 0 |
| Susquehanna International Group, Llp | 34.94K | ▲ 21.92K |
Held by 6 ETFs
Biggest fund positions in APRE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | Grissinger Michael | other | 12,555 |
| Jun 16, 26 | Grissinger Michael | other | 3,135 |
| Jun 16, 26 | Gruia Gabriela | other | 12,555 |
| Jun 16, 26 | Gruia Gabriela | other | 3,135 |
| Jun 16, 26 | Peters Richard | other | 12,555 |
| Jun 16, 26 | Peters Richard | other | 3,135 |
| Jun 16, 26 | HENNEMAN JOHN B III | other | 3,135 |
| Jun 16, 26 | HENNEMAN JOHN B III | other | 12,555 |
| Jun 16, 26 | BIZZARI JEAN-PIERRE | other | 12,555 |
| Jun 16, 26 | BIZZARI JEAN-PIERRE | other | 3,135 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our APRE coverage
Recent articles, reports, and earnings notes.
No research on APRE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate APRE report →Aprea Therapeutics to Present at October Conferences
globenewswire.com · Oct 5
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
globenewswire.com · Sep 22
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 10
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
globenewswire.com · Aug 28
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
globenewswire.com · Aug 12
Lipocine Appoints Michael J. Grissinger to Board of Directors
prnewswire.com · Aug 3
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
globenewswire.com · Jul 30
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
globenewswire.com · Jun 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.